NSTM on OTC

NovelStem International Corp.

NovelStem International Corp. is an American retail-retail stores company, incorporated in Florida.1 It is headquartered in Boca Raton, Florida.1 Its shares trade on OTC under the symbol NSTM.1

Price unavailable

Last updated Oct 20, 2026.

Overview

Compare with another stock.

  • TickerNSTM on OTC1
  • IndustryRetail-Retail Stores, NEC1
  • HeadquartersBoca Raton, Florida1
  • Incorporated inFL2
  • Business address2255 Glades Rd, Ste 237 W, Boca Raton, Fl 334312
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

22, 1993 and changed its name to NovelStem International Corp. in September 2018.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income4567-$238.8K in 2025−52% since 2021
-$4.0M-$3.0M-$2.0M-$1.0M02021: -$495.5K-$495.5K20212022: -$422.4K-$422.4K2022−15%2023: -$3.5M-$3.5M2023+735%2024: -$927.9K-$927.9K2024−74%2025: -$238.8K-$238.8K2025−74%
Net income4567$2.4M in 2025
-$6.0M-$4.0M-$2.0M0$2.0M$4.0M2021: -$1.3M-$1.3M20212022: -$765.7K-$765.7K2022−43%2023: -$4.2M-$4.2M2023+447%2024: -$3.2M-$3.2M2024−23%2025: $2.4M$2.4M2025

Every line of the income statement as filed: the last 2 fiscal years, latest first.7

Period ending2025-12-312024-12-31
Administrative fee income$12.0K
General and administrative expenses$238.8K$880.9K
Litigation expenses (Note 7)$59.0K
Total operating expenses$238.8K$939.9K
Loss from operations-$238.8K-$927.9K
Loss on derivative instrument$90.0K
Gain on disposal of equity method investment-$1.2M
Relief of indebtedness income-$1.7M
Interest expense$256.2K$425.4K
Total other (income) expenses-$2.6M$515.4K
Income (loss) before income taxes$2.4M-$1.4M
Net income (loss) before equity in net loss of equity method investees$2.4M-$1.4M
Equity in net income (loss) of equity method investees$640-$161.0K
Income from (impairment of) equity method investee, NewStem$5.4K-$1.6M
Net income (loss)$2.4M-$3.2M
Net income (loss) per share - basic$0.05-$0.07
Weighted average number of shares outstanding basic46.9M shares46.9M shares
Net income (loss) per share - diluted$0.05-$0.07
Weighted average number of shares outstanding - diluted47.8M shares46.9M shares

Compare NovelStem International Corp. with another company

What it owns

What NovelStem International Corp. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$6.1K6 Dec 31, 2024$53.1K6 Dec 31, 2023−88.5%

Properties, in its own words

Our corporate office is located at 7740 Cavern Lane, Parkland FL 33067. We believe that our facilities are adequate for current operations.

Item 2 of the 10-K filed Mar 26, 2026.3

Leadership

Who has led NovelStem International Corp., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Mitchell Rubenstein2006–2011

Chair

  1. Mitchell Rubenstein2006–2011

President

  1. Laurie S. Silvers2006–2011
2010201520202025
Board members and other officers (10)

Former names

  • NovelStem International CorpAug 2, 2022 to Aug 2, 20222
  • HOLLYWOOD MEDIA CORPMay 15, 2000 to May 12, 20142
  • HOLLYWOOD COM INCMay 15, 2000 to Aug 14, 20002
  • BIG ENTERTAINMENT INCOct 23, 1996 to Mar 30, 20002

Timeline

  1. Jan 23, 20248-K Change of auditor20
  2. Dec 19, 20238-K Change of auditor21
  3. Jul 13, 20238-K Other events22
  4. Jan 17, 20238-K Executive or director change23
  5. Oct 4, 20228-K Executive or director change24
  6. Feb 14, 2006New chief executive Mitchell Rubenstein becomes CEO10

Filings

43 filings to the SEC since October 2021: 4 annual reports, 12 quarterly reports, 5 major events, 22 other. The latest 20:

  1. Aug 14, 202610-Q EDGAR
  2. May 15, 202610-Q EDGAR
  3. Mar 26, 202610-K EDGAR
  4. Nov 12, 202510-Q EDGAR
  5. Aug 6, 202510-Q EDGAR
  6. May 19, 202510-Q EDGAR
  7. May 15, 2025NT 10-Q EDGAR
  8. Apr 7, 202510-K EDGAR
  9. Apr 1, 2025NT 10-K EDGAR
  10. Nov 14, 202410-Q EDGAR
  11. Aug 14, 202410-Q EDGAR
  12. May 15, 202410-Q EDGAR
  13. Apr 1, 202410-K EDGAR
  14. Jan 23, 20248-K EDGAR
  15. Dec 19, 20238-K EDGAR
  16. Nov 17, 202310-Q EDGAR
  17. Nov 14, 2023NT 10-Q EDGAR
  18. Aug 14, 202310-Q EDGAR
  19. Jul 13, 20238-K EDGAR
  20. Jul 6, 2023UPLOAD EDGAR

The 43 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

SEC filer profile

How NovelStem International Corp. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARNovelStem International Corp.1
  • CIK0000912544
  • Employer ID (EIN)65-03856863
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company3
  • Incorporated inFlorida3
  • Fiscal year endsDecember 311
  • Industry code (SIC)5990 Retail-Retail Stores, NEC1
  • SEC reviewing officeOffice of Trade & Services, Division of Corporation Finance1
  • Business address2255 Glades Rd, Ste 237 W, Boca Raton, FL 334311
  • Phone56199880001
  • Shares outstanding49,332,455 as of Aug 14, 20269
  • Public float$1.3M as of Jun 30, 20253
  • AuditorKreit & Chiu CPA LLP, Los Angeles, California PCAOB ID 6651; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceMay 15, 19961
  • Filings555 in all: 8-K (122), SC 13G/A (57), 10-Q (54), 4 (51), SC 13G (33), CORRESP (22), UPLOAD (21), DEF 14A (18)1
    All 42 form types

    10-K (17), 10QSB (12), 5 (12), NT 10-Q (11), S-3/A (11), S-3 (9), 10-K/A (8), 3 (8), SC 13D (8), SC 13D/A (8), DEFA14A (7), NT 10-K (6), REGDEX (6), S-8 (6), S-8 POS (6), 10-Q/A (5), 424B3 (5), 10-12G/A (4), 8-K/A (4), PRER14A (4), PRE 14A (3), SC TO-I/A (3), 10KSB (2), 4/A (2), 10-12G (1), 10-K405 (1), 10KSB40 (1), 10QSB/A (1), 15-12B (1), 25 (1), DEFM14A (1), PREM14A (1), S-3MEF (1), SC TO-I (1)

  • Latest filingsAnnual report (10-K) Mar 26, 2026
    Quarterly report (10-Q) Aug 14, 2026
    Proxy statement (DEF 14A) Nov 18, 2013
    Latest 8-K (8-K) Jan 23, 2024

Risk factors and legal proceedings

The risks NovelStem International Corp. names in Item 1A of its 10-K filed Mar 26, 2026: 11 risks under these headings, as written.3

  • Risks Relating to our Business
  • We are a holding company, the principal assets of which are illiquid rights to a licensing agreement.
  • We depend on our executive officers and consultants and other key individuals along with the executive officers and key individuals of NewStem to continue the implementation of our long-term business strategy and could be harmed by the loss of their services and our inability to make up for such loss with qualified replacements.
  • We have limited operating histories and have generated minimal revenue to date.
  • We have identified material weaknesses in our internal control and procedures and internal control over financial reporting. If not remediated, our failure to establish and maintain effective disclosure controls and procedures and internal control over financial reporting could result in material misstatements in our financial statements and a failure to meet our reporting and financial obligations, each of which could have a material adverse effect on our financial condition and the trading price of our common stock.
  • Rapid technological change could cause the License to become obsolete.
  • Risks relating to our common stock
  • Because our holding company structure creates restrictions on the payment of dividends, our ability to pay dividends is limited.
  • Because we do not intend to pay any cash dividends on our common stock, our shareholders will not be able to receive a return on their shares unless they sell them.
  • Reporting requirement under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and compliance with the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”), including establishing and maintaining acceptable internal controls over financial reporting, are costly and may increase substantially.
  • There is a very limited trading market for our common stock and investors are not assured of the opportunity to sell their stock, should they desire to do so.
  • The price of our common stock could be highly volatile.
The other 1 risk
  • We may be deemed an investment company, which could impose on us burdensome compliance requirements.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
    SEC EDGAROther events
  23. 23
  24. 24